High incidence of septic shock caused by Streptococcus pneumoniae serotype 3 - a retrospective epidemiological study

BMC Infectious Diseases

Kristian Riesbeck²  Fredrik Resman¹  Inga Odenholt¹  Arne Forsgren²  Nils Littorin²  Jonas Ahl¹ 

[1] Department of Clinical Sciences, Infectious Diseases Research Unit, Malmö, Lund University, SE-205 02 Malmö, Sweden;Department of Laboratory Medicine Malmö, Medical microbiology, SE-205 02 Malmö, Sweden

关键词: Streptococcus pneumoniae;    Serotype 19F;    Serotype 3;    Sepsis;    Invasive pneumococcal disease;   

Others  :  1145681
DOI  :  10.1186/1471-2334-13-492

 received in 2013-04-12, accepted in 2013-10-16,  发布年份 2013

【 摘 要 】

Background

More than 90 immunologically distinct serotypes of Streptococcus pneumoniae exist, and it is not fully elucidated whether the serotype is a risk factor for severity of invasive pneumococcal disease (IPD). Our hypothesis is that serotypes differ in their capacity to cause septic shock.

Methods

We performed a retrospective study in Southern Sweden based upon 513 patients with IPD in the pre-vaccine era 2006–2008. The serotype, co-morbidity, and sepsis severity were determined. Serotypes were compared to serotype 14 as a reference and grouped according to their invasive potential, that is, high (serogroups 1, 5 and 7), intermediate (serogroups 4, 9, 14 and 18) and, finally, low invasive potential (serogroups 3, 6, 8, 15, 19, 23 and 33).

Results

Patients with S. pneumoniae serotype 3 had significantly more often septic shock (25%, odds ratio (OR) 6.33 [95% confidence interval (CI) 1.59-25.29]), higher mortality (30%, OR 2.86 [CI 1.02-8.00]), and more often co-morbidities (83%, OR 3.82 [CI 1.39-10.54]) when compared to serotype 14. A significant difference in age and co-morbidities (p≤0.001) was found when patient data were pooled according to the invasive potential of the infecting pneumococci. The median age and percentage of patients with underlying co-morbidities were 72 years and 79%, respectively, for serogroups associated with low invasiveness, 68 years and 61%, respectively, for serogroups with intermediate invasiveness, and, finally, 62 years and 48%, respectively, for serogroups with high invasiveness. No difference in sepsis severity was found between the three groups.

Conclusions

S. pneumoniae serotype 3 more often caused septic shock compared to serotype 14. Our results support the hypothesis that serotypes with high invasiveness mainly cause IPD in younger patients with less co-morbidities. In contrast, serogroups with low and intermediate invasive potential mostly cause IPD in the elderly with defined co-morbidities, and thus can be considered as opportunistic.

【 授权许可】

   
2013 Ahl et al.; licensee BioMed Central Ltd.

【 参考文献 】

• [1]van der Poll T, Opal SM: Pathogenesis, treatment, and prevention of pneumococcal pneumonia. Lancet 2009, 374(9700):1543-1556.
• [2]Weiser JN: The pneumococcus: why a commensal misbehaves. J Mol Med (Berl) 2009, 88(2):97-102.
• [3]Brueggemann AB, Peto TE, Crook DW, Butler JC, Kristinsson KG, Spratt BG: Temporal and geographic stability of the serogroup-specific invasive disease potential of Streptococcus pneumoniae in children. J Infect Dis 2004, 190(7):1203-1211.
• [4]Jansen AG, Rodenburg GD, van der Ende A, van Alphen L, Veenhoven RH, Spanjaard L, et al.: Invasive pneumococcal disease among adults: associations among serotypes, disease characteristics, and outcome. Clin Infect Dis 2009, 49(2):e23-e29.
• [5]Sjostrom K, Spindler C, Ortqvist A, Kalin M, Sandgren A, Kuhlmann-Berenzon S, et al.: Clonal and capsular types decide whether pneumococci will act as a primary or opportunistic pathogen. Clin Infect Dis 2006, 42(4):451-459.
• [6]Alanee SR, McGee L, Jackson D, Chiou CC, Feldman C, Morris AJ, et al.: Association of serotypes of streptococcus pneumoniae with disease severity and outcome in adults: an international study. Clin Infect Dis 2007, 45(1):46-51.
• [7]Berg S, Trollfors B, Persson E, Backhaus E, Larsson P, Ek E, et al.: Serotypes of Streptococcus pneumoniae isolated from blood and cerebrospinal fluid related to vaccine serotypes and to clinical characteristics. Scand J Infect Dis 2006, 38(6–7):427-432.
• [8]Harboe ZB, Thomsen RW, Riis A, Valentiner-Branth P, Christensen JJ, Lambertsen L, et al.: Pneumococcal serotypes and mortality following invasive pneumococcal disease: a population-based cohort study. PLoS Med 2009, 6(5):e1000081.
• [9]Martens P, Worm SW, Lundgren B, Konradsen HB, Benfield T: Serotype-specific mortality from invasive streptococcus pneumoniae disease revisited. BMC Infect Dis 2004, 4:21. BioMed Central Full Text
• [10]Ruckinger S, von Kries R, Siedler A, van der Linden M: Association of serotype of Streptococcus pneumoniae with risk of severe and fatal outcome. Pediatr Infect Dis J 2009, 28(2):118-122.
• [11]Weinberger DM, Harboe ZB, Sanders EA, Ndiritu M, Klugman KP, Ruckinger S, et al.: Association of serotype with risk of death due to pneumococcal pneumonia: a meta-analysis. Clin Infect Dis 2010, 51(6):692-699.
• [12]Garcia-Vidal C, Ardanuy C, Tubau F, Viasus D, Dorca J, Linares J, et al.: Pneumococcal pneumonia presenting with septic shock: host- and pathogen-related factors and outcomes. Thorax Jan 2010, 65(1):77-81.
• [13]Briles DE, Crain MJ, Gray BM, Forman C, Yother J: Strong association between capsular type and virulence for mice among human isolates of Streptococcus pneumoniae. Infect Immun 1992, 60(1):111-116.
• [14]Kahlmeter G: The Swedish refence group for antibiotics (SRGA) and its subcommittee on methodology (SRGA-M). The Swedish refence group for Antibiotics (SRGA) and its subcommittee on methodology (SRGA-M); 2011. [updated 2011-02-21]; Available from: http://www.srga.org webcite
• [15]Claesson BHH, Nyberg A, Thore M, Wollin R, Akerlind B: Referensmetodik för laboratoriediagnostik vid kliniska mikrobiologiska laboratorier. Swedish Institute for Infectious Disease Control; 2005. [cited 2011 2011-01-01]; Available from: http://www.referensmetodik.smi.se/w/Huvudsida webcite
• [16]Halbert SP, Swick L, Sonn C: The use of precipitin analysis in agar for the study of human streptococcal infections: II ouchterlony and oakley technics. J Exp Med 1955, 101(5):557-576.
• [17]Lund EHJ: Laboratory diagnosis, serology and epidemiology of streptococcus pneumoniae. New York: Academic Press; 1978.
• [18]Austrian R: The quellung reaction, a neglected microbiologic technique. Mt Sinai J Med 1976, 43(6):699-709.
• [19]Inghammar M, Engstrom G, Lofdahl CG, Egesten A: Validation of a COPD diagnosis from the Swedish inpatient registry. Scand J Public Health Dec 2012, 40(8):773-776.
• [20]Dellinger RP, Levy MM, Carlet JM, Bion J, Parker MM, Jaeschke R, et al.: Surviving sepsis campaign: international guidelines for management of severe sepsis and septic shock: 2008. Crit Care Med 2008, 36(1):296-327.
• [21]Furebring MBM, Cronqvist J, Follin P, Gille-Johnsson P, Gårdlund B, Lanbeck P, Ljungström L, Otto G, Sjölin J, Svefors J, Vikerfors J: Vårdprogram svår sepsis och septisk chock - tidig identifiering och initial handläggning. 2008. [cited 2011 2011-01-01]; Available from: http://www.infektion.net/klinik/Sepsis/Vardprogram_Sepsis.pdf webcite
• [22]Feikin DR, Klugman KP: Historical changes in pneumococcal serogroup distribution: implications for the era of pneumococcal conjugate vaccines. Clin Infect Dis 2002, 35(5):547-555.
• [23]Wood WB Jr, Smith MR: The inhibition of surface phagocytosis by the capsular slime layer of pneumococcus type III. J Exp Med 1949, 90(1):85-96.
• [24]Poolman J, Borrow R: Hyporesponsiveness and its clinical implications after vaccination with polysaccharide or glycoconjugate vaccines. Expert Rev Vaccines 2011, 10(3):307-322.
• [25]Dagan RPS, Juergens C, Greenberg D, Givon-Lavi N, Gurtman A, Kohberger K, Gruber WC, Scott DA: The efficacy of the 13-valent pneumococcal conjugate vaccine (PCV13) additional serotypes on nasopharyngeal colonization. Foz do Iguaçu, Brazil: Iguaçu Falls, Brazil; 2012. [A randomized double-blind pediatric trial the 8th international symposium of pneumococci and pneumococcal disease] p. Abstract 312
• [26]Weil-Olivier C, van der Linden M, de Schutter I, Dagan R, Mantovani L: Prevention of pneumococcal diseases in the post-seven valent vaccine era: a European perspective. BMC Infect Dis 2012, 12:207. BioMed Central Full Text